Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING-2 hydroxyurea primary stroke prevention trial in Nigerian children with sickle cell disease
PACTR202312522038774Phase 4Not yet recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroxyurea in sickle cell disease (SCD), sponsored by Vanderbilt University Medical Center. Primary endpoints: Incident stroke or transient ischemic attack and Capacity building for data coordinating center and DSMB functions. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202312522038774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202312522038774.